Assignee

Alnylam Pharmaceuticals, Inc.

Patents = 436

Trademarks = 38

Forward Citations = 5,141

where 'Filed Patents' based on already Granted Patents

where 'Inventors Filed' based on already Granted Patents

347 inventors (with patents filed for the assignee):

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing RNA interference (RNAi) therapies for a wide range of diseases. Using its proprietary RNAi technology, the company aims to silence or inhibit the expression of specific genes known to cause diseases. Alnylam's innovative approach has the potential to revolutionize the treatment of various genetic and rare diseases. For more information, please visit their official website.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com